A £37 million Bioscience Campus is to be set up at GlaxoSmithKline’s site at Stevenage, UK, with funding from the government, GlaxoSmithKline, and other partners.
In the highest value deal yet seen for a preclinical pipeline, GlaxoSmithKline plc swooped on Domantis Ltd, paying £230 million cash for the six-year-old UK Medical Research Council spin out.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.